The FDA approved daratumumab and hyaluronidase-fihj for adults with smoldering multiple myeloma that has a high risk of progression. The U.S. Food and Drug Administration (FDA) has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) as...
De-escalating treatment for patients with chronic cancers can be beneficial for overall mental health. Patients with chronic lymphocytic leukemia (CLL) are typically treated with Bruton’s tyrosine kinase inhibitors, or BTKis. Although effective, patients typically...
The FDA is proposing a cap on nicotine in cigarettes that would reduce the amount by 95%, which could help to save millions of lives.
Promising early-phase clinical trial data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Researchers are exploring innovative early cancer detection strategies involving tiny cancer hunters, the voice, electronic noses, and more.
People with history of polyps often do not get follow-up colonoscopy after a positive FIT test, and early-onset cancers are rising in Corn Belt states.
Adding chemotherapy to targeted therapy improves outcomes for people with advanced EGFR-positive non-small cell lung cancer.
Since 1993, the American Association for Cancer Research (AACR) has invested more than $542 million in grants to sustain the pipeline of cancer researchers and accelerate breakthroughs for patients. The second annual AACR Grantee...
A look at recent research on determining breast cancer risk, the impact of lifestyle changes on cancer risk, and why screening is important.
The FDA has approved the menin inhibitor revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation in certain adult and pediatric patients 1 year and older. The U.S. Food and...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More